Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study

By sjmartinez • July 13, 2024

Narasaki Y, Kovesdy CP, You AS, Sumida K, Mallisetty Y, Surbhi S, Thomas F, Amin AN, Streja E, Kalantar-Zadeh K, Rhee CM. Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study. Lancet Reg Health Am. 2024 Jun 18;36:100814. doi: 10.1016/j.lana.2024.100814. PMID: 38993538; PMCID: PMC11237921.

Tags: Harbor UCLA, Nephrology, Publications, Veterans Administration

Patient-Level Perivascular Adipose Tissue Density Aggregation and Plaque Progression: Plaque-Free vs Plaque-Adjacent Segments

Lee SE, Sung JM, Andreini D, Al-Mallah MH, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Chun EJ, Conte E, Gottlieb I, Hadamitzky M, Kim[...]

Corrigendum to “Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.” Kidney International 2023;103,565-579

Mariani LH, Eddy S, AlAkwaa FM, McCown PJ, Harder JL, Nair V, Eichinger F, Martini S, Ademola AD, Boima V, Reich HN, El Saghir J,[...]

Heart failure and atrial fibrillation prediction from non-gated chest CT scans using AI-based cardiac chamber volumetry: an AI-CVD study within the multi-ethnic study of atherosclerosis (MESA)

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]